SNSS - Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics
CymaBay Therapeutics (CBAY): The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for changes in liver fat, lipids, and transaminases at Week 12 is expected before the end of Q2. Keep in mind that, a few months ago, the drug candidate was awarded the coveted Breakthrough Therapy designation by the FDA for patients with early-stage PBC (primary biliary cholangitis) and that the company's operational runway